Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Gligorov

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas|December 11, 2014
Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancerF Selle, J Gligorov, S Richard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2014
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer studyX Pivot, J Gligorov, V Müller, et al.
Gynecologie, Obstetrique & Fertilite|October 26, 2005
[The use of GnRH analogues in early and advanced breast carcinomas]C Ségura, D Avenin, J Gligorov, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2017
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer studyX Pivot, S Verma, L Fallowfield, et al.
Bulletin Du Cancer|February 16, 2000
[High-dose chemotherapy in ovarian adenocarcinoma]J P Lotz, C Lhommé, P Pautier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2011
Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant settingR Rouzier, G Werkoff, C Uzan, et al.
Bone Marrow Transplantation|September 1, 1996
The ICE regimen (ifosfamide, carboplatin, etoposide) for the treatment of germ-cell tumors and metastatic trophoblastic diseaseJ P Lotz, T André, C Bouleuc, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2017
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJ Gligorov, B Ataseven, M Verrill, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2011
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclinesE Curtit, P Nouyrigat, N Dohollou, et al.
British Journal of Cancer|July 15, 2010
Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patientsA Fajac, J Gligorov, K Rezai, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas|December 11, 2014
Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancerF Selle, J Gligorov, S Richard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2014
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer studyX Pivot, J Gligorov, V Müller, et al.
Gynecologie, Obstetrique & Fertilite|October 26, 2005
[The use of GnRH analogues in early and advanced breast carcinomas]C Ségura, D Avenin, J Gligorov, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2017
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer studyX Pivot, S Verma, L Fallowfield, et al.
Bulletin Du Cancer|February 16, 2000
[High-dose chemotherapy in ovarian adenocarcinoma]J P Lotz, C Lhommé, P Pautier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2011
Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant settingR Rouzier, G Werkoff, C Uzan, et al.
Bone Marrow Transplantation|September 1, 1996
The ICE regimen (ifosfamide, carboplatin, etoposide) for the treatment of germ-cell tumors and metastatic trophoblastic diseaseJ P Lotz, T André, C Bouleuc, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2017
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJ Gligorov, B Ataseven, M Verrill, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2011
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclinesE Curtit, P Nouyrigat, N Dohollou, et al.
British Journal of Cancer|July 15, 2010
Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patientsA Fajac, J Gligorov, K Rezai, et al.
Pageof 7